Pharmaceutical innovation and parallel trade

Berndt, 2007, Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness, Health Econ., 16, 491, 10.1002/hec.1176 Chard, 1989, Intellectual property rights and parallel imports, World Econ., 12, 69, 10.1111/j.1467-9701.1989.tb00464.x Chaudhuri, 2006, Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India, Am. Econ. Rev., 96, 1477, 10.1257/aer.96.5.1477 Chen, Y., Schwartz, M., 2013. Differential pricing when costs differ: a welfare analysis, mimeo. Danzon, 1997, Price discrimination for pharmaceuticals: welfare effects in the US and the EU, Int. J. Econ. Bus., 4, 301, 10.1080/758523212 Danzon, 2000, Does regulation drive out competition in pharmaceutical markets?, J. Law Econ., 43, 311, 10.1086/467458 Danzon, 2003, Differential pricing for pharmaceuticals: reconciling access, R&D and patents, J. Health Care Finance Econ., 3, 183, 10.1023/A:1025384819575 Fink, 2005, Tightening TRIPS: the intellectual property provisions of recent US free trade agreements Gallini, 1999, A contractual approach to the gray market, Int. Rev. Law Econ., 19, 1, 10.1016/S0144-8188(98)00032-5 Ganslandt, 2004, Parallel imports and the pricing of pharmaceutical products: evidence from the EU, J. Health Econ., 23, 1035, 10.1016/j.jhealeco.2004.03.005 Goldberg, 2010, Intellectual property rights protection in developing countries: the case of pharmaceuticals, J. Eur. Econ. Assoc., 8, 326, 10.1111/j.1542-4774.2010.tb00506.x Grossman, 2008, Parallel imports and price control, RAND J. Econ., 39, 378, 10.1111/j.0741-6261.2008.00019.x Jelovac, 2005, Pricing and welfare implications of parallel imports in the pharmaceutical industry, Int. J. Health Care Finance Econ., 5, 5, 10.1007/s10754-005-6599-x Kanavos, 2005, Pharmaceutical parallel trade in Europe: stakeholder and competition effects, Econ. Policy, 20, 751, 10.1111/j.1468-0327.2005.00150.x Kyle, 2007, Pharmaceutical price controls and entry strategies, Rev. Econ. Stat., 89, 88, 10.1162/rest.89.1.88 Kyle, 2009, Parallel trade in pharmaceuticals: firm responses and competition policy Li, 2006, The impact of parallel imports on investment in cost-reducing R&D, J. Int. Econ., 68, 443, 10.1016/j.jinteco.2005.07.006 Malueg, 1994, Parallel imports, demand dispersion, and international price discrimination, J. Int. Econ., 37, 167, 10.1016/0022-1996(94)90044-2 Maskus, 2000 Maskus, 2004, Vertical pricing and parallel imports: theory and evidence, Rev. Int. Econ., 12, 419, 10.1111/j.1467-9396.2004.00467.x Mussa, 1978, Monopoly and product quality, J. Econ. Theory, 18, 301, 10.1016/0022-0531(78)90085-6 Pecorino, 2002, Should the US allow prescription drug reimports from Canada?, J. Health Econ., 21, 699, 10.1016/S0167-6296(02)00035-8 Roy, 2012, Equilibrium parallel import policies and international market structure, J. Int. Econ., 87, 262, 10.1016/j.jinteco.2012.01.007 Saggi, 2013, Market power in the global economy: the exhaustion and protection of intellectual property, Econ. J., 123, 131, 10.1111/j.1468-0297.2012.02544.x Valletti, 2006, Differential pricing, parallel trade, and the incentive to invest, J. Int. Econ., 70, 314, 10.1016/j.jinteco.2005.07.010 Valletti, 2006, Parallel trade, international exhaustion and IPRs: a welfare analysis, J. Ind. Econ., 54, 499, 10.1111/j.1467-6451.2006.00298.x WHO, 2002